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B. In arm A an overall RR of 20% (95% CI 7.7–38.6%) was seen, 
and 18.2% (95% CI 7–35.5%) in arm B.  Conclusions: Although 
the study was prematurely closed, the current data are of 
interest. The schedule with carboplatin on day 8 is associated 
with substantially lower grade 3–4 neutropenia and throm-
bocytopenia with comparable dose intensity and RR. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Lung cancer is the leading cause of cancer-related 
deaths in many countries. Approximately one third of pa-
tients with non-small cell lung cancer (NSCLC) have 
metastatic disease at the time of diagnosis. Platinum-
based chemotherapy remains the standard chemothera-
py regimen in metastatic NSCLC  [1] . Although recent 
meta-analyses showed a marginal statistical superiority 
of a combination of cisplatin with third-generation drugs 
 [2, 3] , many clinicians feel that this improvement is large-
ly counterbalanced by the increased toxicity of the cis-
platin regimen. As a consequence, the carboplatin-gem-
citabine regimen is frequently used in Europe as it results 
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 Abstract 
 Purpose: Carboplatin area under the curve (AUC) 5 ml/min 
on day 1 with gemcitabine 1,250 mg/m 2 on day 1 and day 8 
is a widely used regimen in advanced non-small cell lung 
cancer. Grade 3–4 thrombocytopenia and neutropenia are 
frequent. The aim of this study is to investigate whether tox-
icity of gemcitabine/carboplatin could be reduced by ad-
ministering carboplatin on day 8 instead of day 1 without a 
decrease in response rate (RR).  Methods: Patients received 
gemcitabine 1,250 mg/m 2 on days 1 and 8, carboplatin AUC 
5 on day 1 (arm A) or day 8 (arm B). Drugs were administered 
over a 21-day cycle. Toxicity and RR were evaluated weekly 
and every second cycle, respectively.  Results: 71 patients 
were enrolled into the study. We found 79% (95% CI 61–91%) 
grade 3–4 toxicity (neutropenia and thrombocytopenia) in 
arm A and 50% (95% CI 32–68%) in arm B; 66% grade 3–4 
thrombocytopenia in arm A and 26% in arm B. We observed 
30% grade 4 hematological toxicity in arm A and 3% in arm 
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in less severe neurotoxicity, nephrotoxicity, nausea and 
vomiting.
 Dose-limiting toxicity in the gemcitabine/carboplatin 
chemotherapy regimen is hematological  [4, 5] . In the 
3-weekly regimen in which gemcitabine and carboplatin 
are administered on day 1 and gemcitabine again on day 
8, thrombocytopenia grade 3–4 was found in more than 
40% of cases, neutropenia grade 3–4 in 20%  [6] .
 The hypothesis of the present study was that adminis-
tration of carboplatin on day 8 instead of day 1 would 
result in less hematological toxicity without compromis-
ing the activity of the combination.
 Methods 
 Patient Selection 
 Patients with histologically or cytologically proven stage IV or 
IIIB NSCLC with malignant pleural effusion or supraclavicular 
lymph nodes were eligible. Other criteria were measurable disease 
according to RECIST  [7] , age  6 18 years, WHO  ! 2, and adequate 
bone marrow reserve. No prior chemotherapy for NSCLC was al-
lowed. The study was approved by the ethical committee of the 
Erasmus MC and all participating hospitals. Patients were includ-
ed after obtaining their written informed consent.
 Treatment Plan 
 Patients in arm A were treated with gemcitabine (1,250 mg/m 2 
days 1, 8) and carboplatin (area under the curve, AUC, 5 ml/min 
day 1). Patients in arm B were treated with gemcitabine (1,250
mg/m 2 days 1, 8) and carboplatin (AUC 5 ml/min day 8). Both 
drugs were administered as a 21-day cycle. Treatment was given 
for a maximum of 4 courses. Tumor response was assessed every 
second cycle. The dose of gemcitabine was reduced to 1,000 mg/
m 2 and the carboplatin dose to AUC 4 if the nadir of the absolute 
neutrophil count (ANC) was  ! 0.5  ! 10 9 /l and/or the nadir of the 
platelets was  ! 50  ! 10 9 /l or in case of febrile neutropenia or se-
vere bleeding (grade 4). If on day 21 the white blood count (WBC) 
was  ! 3  ! 10 9 /l, ANC  ! 1.5  ! 10 9 /l or platelets  ! 100  ! 10 9 /l, treat-
ment was delayed. In case the platelets were  ^  50  ! 10 9 /l and/or 
the WBC  ^  1  ! 10 9 /l and/or the ANC  ^  0.5  ! 10 9 /l on day 8, no 
carboplatin or gemcitabine was given. In all other cases no dose 
reduction for carboplatin on day 8 was allowed.
 Efficacy and Tolerability Assessments 
 Study assessments included physical examination, complete 
blood count, electrocardiogram, chest-upper abdomen computed 
tomography scan (CT), bone scan or PET-scan. Routine blood 
tests were performed before each chemotherapy administration. 
Toxicity was graded according to the National Cancer Institute 
Common Toxicity Criteria version 2 (NCI-CTC) and assessed on 
days 1, 8, 15 and 21 of each cycle. 
 Study Design, Statistical Considerations and Analysis 
 The study was an open multicenter randomized phase II trial. 
All participants were stratified by institution, disease stage, WHO 
performance status, gender and age. A Bryant and Day design was 
used to simultaneously assess response rate and hematological 
toxicity as co-primary endpoints  [8] . Secondary endpoints were 
overall survival and 1-year survival.
 Based on predefined expectations that arm A (carbo/gem day 
1) is associated with a grade 3–4 toxicity (thrombocytopenia and 
neutropenia) in 30% of cases with a response rate of 45% and that 
arm B (carbo/gem day 8) is associated with 15% grade 3–4 toxic-
ity and a response rate of 45%, we designed the study as follows. 
Considering P 0 = 30% (unacceptable response rate) and P 1 = 50% 
(acceptable response rate), and T 0 = 30% (unacceptable toxicity 
rate) and T 1 = 15% (acceptable toxicity rate), with an alpha of 0.10 
and a power of 90%, the sample size was estimated to be 67 pa-
tients in each arm. A first-stage analysis was planned for 54 pa-
tients. The following rule was applied for both arms: if 8 or less 
patients showed a response and/or 8 or more patients developed 
grade 3–4 thrombocytopenia and/or neutropenia, closure of the 
arm was necessary. Patients who did not receive any treatment 
were excluded from the toxicity analysis and patients for whom 
response was not assessed due to early death or early discontinu-
ation were excluded from the activity analysis.
 Response and toxicity rates, including 95% CIs, were com-
pared using a Pearson’s   2 test. Survival was estimated according 
to Kaplan Meier.
 Results 
 Patients and Disease Characteristics 
 A total of 71 patients were enrolled between April 2004 
and March 2006, before the planned first stage analysis. 
71 patients were included instead of 54 because not all 
patients were evaluable for response and results of the 
first stage analysis were not immediately available. 
 Patient and disease characteristics at baseline for the 
69 eligible patients are summarized in  table 1 .
 Dose Administration and Intensity 
 Median dose intensity for gemcitabine in arm A was 
708 mg/m 2 /week (range 189–847) and in arm B 804
mg/m 2 /week (range 314–849). Relative dose intensity was 
85% in arm A and 96% in arm B. The median total car-
boplatin dose in arm A was 1,830 mg versus 2,090 mg in 
arm B. Gemcitabine day 1 dose reductions occurred in 
9% of cycles in arm A and in 3% in arm B. For gemcitabi-
ne day 8, dose adjustments occurred in 11% of cycles in 
arm A and in 5% in arm B. Carboplatin doses were re-
duced in 9% of cycles in arm A and in only 1% in arm B.
 Toxicity 
 The frequency of toxicity check was weekly with 7% 
missing values for ANC and/or platelets in arm A com-
pared to 6% in arm B.
 Table  2 shows grade 3–4 toxicity (neutropenia and 
thrombocytopenia) of 79% (95% CI 61–91%) in arm A 
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and 50% (95% CI 32–68%) in arm B. Grade 3–4 throm-
bocytopenia occurred in 66% of patients in arm A and in 
26% in arm B. Platelet transfusions were required in 14% 
of patients in arm A and in 0% in arm B. 
 Response and Outcome 
 Five of 69 patients were considered unassessable for 
response evaluation as they did not receive at least 2 cy-
cles of therapy. In the remaining 64 patients, we observed 
1 complete response and 11 partial responses; 40 patients 
remained stable and 12 progressed under treatment, ei-
ther radiologically and/or clinically.
 In arm A, an overall response rate of 20% (95% CI 7.7–
38.6%) was seen compared with 18.2% (95% CI 7–35.5%) 
in arm B. The median survival time for all patients was 
7.3 months, with a 1-year survival rate of 28%. Median 
survival was 9.4 months for arm A and 6.8 months for 
arm B.
 Discussion 
 With carboplatin-gemcitabine being widely used as 
the standard regimen in advanced NSCLC, we wanted to 
investigate whether the administration of carboplatin on 
day 8 instead of day 1 could reduce hematological toxic-
ity without loss of activity. Based on the early stopping 
rule, the study was closed prematurely as response rates 
in both arms were lower and toxicities higher than ex-
pected. Compared to other trials, grade 3–4 hematologi-
cal toxicity in the present study was high. This probably 
reflects the weekly sampling instead of sampling at re-
treatment or at clinical toxicities only. Another reason for 
the premature closure could be that the cut-off value for 
acceptable/unacceptable response and toxicity in the 
standard arm was too optimistic. Survival in arm B is 
lower than reported in the literature, but also survival in 
the standard arm is low. This is probably due to a high 
percentage of patients (81%) with stage IV disease. A lim-
itation of the study is that the sample size is too small to 
reasonably consider any comparisons between the two 
arms in terms of survival, although survival in arm B 
seems lower compared to the standard arm.
 The study did not meet its primary endpoint, but the 
data are of interest. Response rates were found to be sim-
ilar but we observed a considerably lower rate of hemato-
logical toxicity by administering carboplatin on day 8 
with preservation of dose intensity.
 Although a combination of cisplatin with third-gener-
ation drugs shows a marginal statistical superiority, many 
clinicians prefer the carboplatin-based regimens because 
of the better tolerance and the difficult logistics of cis-
platin administration. Gemcitabine/carboplatin is fre-
quently used in Europe for patients with advanced NSCLC 
 [9, 10] . This regimen is well tolerated, but clinicians fre-
quently have to deal with grade 3–4 neutropenia and 
Table 1.  Patient and disease characteristics
Overall Arm A Arm B
Number of patients 69 34 35
Gender
Male
Female
52 (75)
17 (25)
25
9
27
8
Age, years
Median
Range
61
39–77
61
41–77
61
39–74
ECOG performance
0
1
11 (16)
58 (84)
6
28
5
30
Stage of disease
IIIB
IV
13 (19)
56 (81)
6
28
7
28
Histology
Squamous
Adenocarcinoma
Other
14 (20)
33 (48)
22 (32)
8
17
9
6
16
13
Numbers in parentheses are percentages.
Table 2.  Hematological toxicities and response
Toxicity Arm A (n = 33) Arm B (n = 34)
Platelets/ANC grade 3–4 26 (79) 17 (50)
Platelets/ANC grade 4 10 (30) 1 (3)
Platelets grade 3–4 22 (67) 9 (26)
ANC grade 3–4 18 (55) 12 (35)
ANC grade 4 10 (30) 1 (3)
Platelets grade 4 1 (3) 0 (0)
Response
CR
PR
SD
PD
0
6
21
3
1
5
19
9
Overall RR, % 20 18
P ercent values are shown in parentheses.
CR = Complete response; PR = partial response; SD = stable 
disease; PD = progressive disease.
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grade 3–4 thrombocytopenia. Even though severe bleed-
ing problems are not seen very often, physicians feel un-
comfortable about thrombocytopenia because it neces-
sitates more attention, repeated platelet count controls, 
dose reductions and platelet transfusions  [11]. The Nor-
wegian Lung Cancer Study Group recently also reported 
on a grade 3 thrombocytopenia of 25% and grade 4 
thrombocytopenia of 19% in the carboplatin day 1-gem-
citabine regimen, resulting in more frequent platelet 
transfusions and higher costs  [12] . Reducing hematologi-
cal toxicity is important especially in patients with meta-
static disease, in whom quality of life is still a major goal.
 Conclusion 
 Although the study was stopped prematurely, we be-
lieve that the current data are of interest. With compa-
rable dose intensity and response rate, the schedule with 
carboplatin on day 8 is associated with a substantially 
lower rate of grade 3–4 neutropenia and thrombocytope-
nia. The observed possibly lower median survival trend 
merits further investigation. 
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